Sun Catherine Q, Chen Tiffany A, Deiner Michael S, Ou Yvonne
Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.
Clin Ophthalmol. 2021 Jan 22;15:243-251. doi: 10.2147/OPTH.S285136. eCollection 2021.
There is limited long-term data comparing selective laser trabeculoplasty (SLT) to the newer micropulse laser trabeculoplasty (MLT) using a laser emitting at 532 nm. In this study, we determine the effectiveness and safety of MLT compared to SLT.
Retrospective comparative cohort study.
A total of 85 consecutive eyes received SLT and 43 consecutive eyes received MLT.
Patients with open-angle glaucoma receiving their first treatment of laser trabeculoplasty were included. Exclusion criteria are prior laser trabeculoplasty, laser cyclophotocoagulation or glaucoma surgery, and follow-up of less than 1 year.
The primary outcome was success at 1 year, defined as a reduction in intraocular eye pressure (IOP) by ≥20% from baseline or met prespecified target IOP with no additional glaucoma medication or subsequent glaucoma intervention.
Baseline IOP was 18.0 mmHg (95% CI=16.4-19.5) in the MLT group on an average of 1.8 (95% CI=1.4-2.2) glaucoma medications compared to 18.2 mmHg (95% CI=17.2-19.3) for the SLT group on an average of 2.0 (95% CI=1.6-2.3) medications. At 1-hour post-laser, the SLT group had more transient IOP spikes (MLT 5% vs SLT 16%, =0.10). There was a trend toward increased success in the SLT group compared to MLT at 1 year (relative risk=1.4, 95% CI=0.8-2.5, =0.30).
Eyes had similar success after MLT compared to SLT at 1 year. Laser trabeculoplasty with either method could be offered as treatment with consideration of MLT in those eyes where IOP spikes should be avoided.
比较选择性激光小梁成形术(SLT)与采用532纳米波长激光的新型微脉冲激光小梁成形术(MLT)的长期数据有限。在本研究中,我们确定了MLT相较于SLT的有效性和安全性。
回顾性比较队列研究。
共有85只连续的眼睛接受了SLT治疗,43只连续的眼睛接受了MLT治疗。
纳入首次接受激光小梁成形术治疗的开角型青光眼患者。排除标准为既往接受过激光小梁成形术、激光睫状体光凝术或青光眼手术,以及随访时间少于1年。
主要结局为1年时的成功情况,定义为眼压(IOP)较基线降低≥20%,或达到预定的目标眼压,且无需额外使用青光眼药物或后续进行青光眼干预。
MLT组的基线眼压为18.0 mmHg(95%置信区间=16.4-19.5),平均使用1.8(95%置信区间=1.4-2.2)种青光眼药物;而SLT组的基线眼压为18.2 mmHg(95%置信区间=17.2-19.3),平均使用2.0(95%置信区间=1.6-2.3)种药物。激光治疗后1小时,SLT组出现更多短暂的眼压峰值(MLT组为5%,SLT组为16%,P=0.10)。1年时,SLT组相较于MLT组有成功增加的趋势(相对风险=1.4,95%置信区间=0.8-2.5,P=0.30)。
1年时,MLT组与SLT组的治疗成功率相似。对于应避免眼压峰值的患者,两种方法的激光小梁成形术均可作为治疗选择,可考虑采用MLT。